Gil Roth11.22.13
Phase I
DelMar presents dose-escalation interim results . . . read more
No dose-limiting toxicity in Threshold study . . . read more
Phase III
Sanofi, Regeneron RA drug shows effectiveness . . . read more
Filings
Biogen idec drug gets protection in EU . . . read more
Eylea approved in Japan . . . read more
J&J diabetes treatment approved in EU . . . read more
Xalkori gets full approval . . . read more
DelMar presents dose-escalation interim results . . . read more
No dose-limiting toxicity in Threshold study . . . read more
Phase III
Sanofi, Regeneron RA drug shows effectiveness . . . read more
Filings
Biogen idec drug gets protection in EU . . . read more
Eylea approved in Japan . . . read more
J&J diabetes treatment approved in EU . . . read more
Xalkori gets full approval . . . read more